^
Association details:
| Biomarker: | Rbsig overexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).
Published date:
05/16/2018
Excerpt:
We collected RNA-sequencing data from pre-treatment biopsies derived from NeoALTTO, a trial randomizing pts with HER2+ early BC to receive lapatinib, trastuzumab or both together with weekly paclitaxel....Overall, pCR rate was significantly higher in pts with RBsig High tumors, than those with RBsig Low (36% vs 18% respectively p = 0.01)….RBsig Low expression identifies a subset of HER2+ pts less likely to respond to CT + H.
Secondary therapy:
paclitaxel
DOI:
10.1200/JCO.2018.36.15_suppl.570
Source:
Title:
A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).
Excerpt:
HER2+ early BC to receive lapatinib, trastuzumab or both together with weekly paclitaxel…RBsig could further stratify HER2e tumors, with RBsig High and Low showing a pCR rate of 44% and 21% respectively (p = 0.02).The pCR rate of HR+/ HER2e/ RBsig High pts was 37% vs 7% for HR+/ HER2e/ RBsig Low (p = 0.04)....RBsig Low expression identifies a subset of HER2+ pts less likely to respond to CT + H.
Secondary therapy:
paclitaxel
DOI:
10.1200/JCO.2018.36.15_suppl.570
